Clinical Trials Logo

Vestibular Schwannoma clinical trials

View clinical trials related to Vestibular Schwannoma.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT04658836 Completed - Clinical trials for Vestibular Schwannoma

Triamcinolone Levels in Cochlear Perilymph, Lateral Canal and CSF

Start date: February 1, 2020
Phase: Phase 1
Study type: Interventional

Patients undergoing surgery of a vestibular schwannoma will be included in the study. Patients will receive triamcinolone acetonide 24h before surgery. During translabyrinthine surgery cochlear perilymph, perilymph from the semicircular canal and cerebrospinal fluid will be taken and analyzed for triamcinolone content. In patients undergoing middle fossa or retrosigmoid resection only cerebrospinal fluid will be taken and analyzed for triamcinolone acetonide level.

NCT ID: NCT04351373 Completed - Clinical trials for Vestibular Schwannoma

Microscopic Fluorescence-guided Vestibular Schwannoma Resection Using Fluorescein Sodium and YELLOW 560

Start date: October 6, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to see if there is benefit to using an IV contrast called AK-Fluor® and a microscope filter called YELLOW560 when surgically removing a vestibular schwannoma, Meningioma, Head and Neck Paraganglioma, or Head and Neck Schwannoma.

NCT ID: NCT04241679 Completed - Clinical trials for Sensorineural Hearing Loss

Auditory Nerve Test System During Vestibular Schwannoma Resection

ANTS
Start date: January 20, 2020
Phase: N/A
Study type: Interventional

The Auditory Nerve Test System (ANTS) is a novel device that stimulates the auditory nerve much like a cochlear implant. The purpose of this study is to demonstrate feasibility of the ANTS during translabyrinthine surgery for vestibular schwannoma resection. If the auditory nerve is kept intact, then the patients will also receive a cochlear implant at the same time potentially alleviating the morbidities caused by a vestibular schwannoma and asymmetric sensorineural hearing loss.

NCT ID: NCT03958006 Completed - Clinical trials for Vestibular Schwannoma

Simultaneous Cochlear Implantation During Translabyrinthine Resection of Vestibular Schwannoma

Start date: December 5, 2018
Phase: N/A
Study type: Interventional

This study will address the feasibility of simultaneous cochlear implantation during resection of a vestibular schwannoma.

NCT ID: NCT03666507 Completed - Clinical trials for Vestibular Schwannoma

Vegetative Monitoring During Brainstem-associated Surgery

Start date: August 28, 2018
Phase:
Study type: Observational

Intraoperative Monitoring of Heart rate variability, Blood pressure variability, Baroreceptorsensivity etc.

NCT ID: NCT03638310 Completed - Clinical trials for Vestibular Schwannoma

Role of Psychiatric Profile in Prehabituated Patients After Vestibular Schwannoma Surgery

Start date: January 1, 2016
Phase: N/A
Study type: Interventional

The aim of this study is to assess effect of psychiatric profile on visual sensitivity and overall health status in patients who underwent surgery for vestibular schwannoma and were prehabituated by chemical vestibular ablation.

NCT ID: NCT03581331 Completed - Visual Impairment Clinical Trials

Consequence of Unilateral Vestibular Loss on Visual Abilities

SVorthoptie
Start date: February 26, 2018
Phase: N/A
Study type: Interventional

Unilateral vestibular lesions are frequent and disabling pathologies causing a set of oculomotor, postural and perceptual symptoms. These symptoms reduce over time according to a vestibular compensation. However, vestibular compensation should be considered as a set of sub-processes whose duration and recovery level differ. Indeed, after a unilateral vestibular loss, some functions remain asymmetrical as a long-term effect, and these disorders may be observed among patients with no functional complaints. Balance disorders may persist in some patients. The equilibration consists in handling real-time a considerable amount of information coming from the environment and the subject himself, allowing an adaptation of the position and movements of his body to satisfy the needs of posture, balance and orientation. This information comes mainly from the vision, the vestibule and the somesthesic system. It is pre-treated and harmonized in the brainstem, before being transmitted to the higher brain centres. Brain centers thus learn about peripheral conditions. According to these and the project of the movement, brain centers address in response orders to ophtalmological and motor effectors ensuring look, posture and balance to be provided. The eye is a cornerstone of the balancing system through the retina, an environmental sensor, and its extraocular muscles, effectors of the system. The aim of this study is to assess the effects of acute unilateral vestibular loss on visual abilities evaluated by orthoptic balance in patients who presented acute unilateral vestibular loss by surgical deafferentation (removal of vestibular schwannoma, vestibular neurotomy or surgical labyrinthectomy for Meniere's disease), during the early phase and decline of vestibular compensation. Our secondary objective is to evaluate the effect of a pre-existing anomaly of the visual abilities evaluated by orthoptic assessment on the vestibular compensation capacities. All in all, this study seems crucial to improve the management of patients with unilateral vestibular dysfunction and contribute to improving their clinical management. As a standardized management of these patients, an audio-vestibular evaluation will be performed before surgery (-1D), after acute unilateral vestibular loss at the early stage (+7D), and then after vestibular compensation (+2M) as well as an orthoptic evaluation. A good tolerance of the orthoptic evaluation is expected in this surgical context.

NCT ID: NCT03210285 Completed - Clinical trials for Vestibular Schwannoma

WES of NF2-associated in Comparison to Sporadic Vestibular Schwannomas - Correlation With Clinical Data

NF2
Start date: July 31, 2017
Phase:
Study type: Observational [Patient Registry]

Whole exome sequencing (WES) of 50 sporadic and 50 Neurofibromatosis Type2 (NF2)-associated vestibularis schwannomas (VS) in children and young adults. The aim is to gain insight into the complete genome of the NF2 associated VS compared to sporadic VS (control group). These data are to be correlated with the clinic, ie the auditory function (audiogram, acoustically evoked potentials) and the clinical picture as well as the tumor growth rate and general data such as sex, age, side, etc.

NCT ID: NCT02963896 Completed - Clinical trials for Vestibular Schwannoma

Vertigo Perception and Quality of Life in Patients After Surgical Treatment of Vestibular Schwannoma

ITG
Start date: January 2014
Phase: N/A
Study type: Interventional

Surgical removal of vestibular schwannoma causes acute vestibular symptoms, including postoperative vertigo and oscilopsia due to nystagmus. In general, the dominant symptom postoperatively is vertigo. Preoperative chemical vestibular ablation can reduce vestibular symptoms postoperatively.

NCT ID: NCT02934256 Completed - Clinical trials for Vestibular Schwannoma

Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors

Icotinib
Start date: July 2016
Phase: Phase 2
Study type: Interventional

1)Preliminarily evaluate the treatment effect of Icotinib Hydrochloride Tablets on NF2; 2)Preliminarily evaluate the safety and the patient's tolerance of the treatment of Icotinib; 3)Provide an objective basis for an enlarged randomized double-blind trial.